3Lohmann V,Komer F,Koch J,et al.Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.Science,2009,285(10):113-116.
4Watanabe K,Yoshioka K,Ito H,et al.The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients wit}l chronic hepatitis C has a similar amino acid sequence with the consensus sequence.Virology,1999,264(1):153-158.
7Caffrey AP,Meuse L,Pham TT,et al.RNA interference in adult mice.Nature,2002,418(3):38-39.
8Guerniou V,Gillet R,Berree F,et al.Targeted inhibition of the hepatitis C internal ribosomal entry site genomic RNA with oligomucleotide conjugates.Nucleic Acids Res,2007,35(10):6778-6787.
1Uriel A J, Fiere D S, Carriero D C, et al. An on-going out break of acute HCV in HIV infected men in New York city Rates of spontaneous clearance and treatment responses[J].Hepatology, 2008, 48(4Suppl): 531A.
2Bruno S, Hadziyannis S J, Shiffman M L, et al. Are there differences in treatment outcomes between HCV genotype 2 and 3 patients with advanced fibrosis treated with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) ?[J]. Hepatology, 2008, 48(4Suppl): 860A.
3Oze T, Hiramatsu N, Yokushijin T, et al. Extended treatment with peginterferon alfa-2b and ribavirin combination therapy can suppress the relapse rate after treatment of chronic hepatitis C genotype 1 patients with late viral response[J]. Hepatology, 2008, 48(4Suppl): 853A.
4Hayashi K, Katano Y, Ishigami M, et al. Mutations in the core and NS5A region of hepatitis C virus genotype lb and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy[J]. Hepatology, 2008, 48(4Suppl) : 848A.
5Elgouhari H M, Cesario K B, Lopez R, etal. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive PTS[J].Hepatology, 2008, 48(4Suppl): 383A.
6Romero-Gomez M, Diago M, Andrade R J, etal. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naive genotype 1 chronic hepatitis C patients with insulin resistance(TRIC-1 ): Final results of randomized and doubleblinded trial[J]. 2008, 48(4Suppl) : 380A.
7Marotta P, Cooper C, Wong D K, et al. Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV Gl-infected patients: Results of the Canadian power program [J]. Hepatology, 2008, 48(4Suppl):849A.
8Schwarz K, Gonzalez-Peralta R P, Murray K F, et al. Pegimerferon with or without ribavirin for chronic hepatitis C in children and adolescents: Final results of the PEDS-C trial[J].Hepatology, 2008, 48(4Suppl):418A.
9Pawlowska M, Pilarczyk M, Halota W, et al. Virologic re- sponse to treatment with pegylated interferon alfa-2h and ribavirin chric hepatitis C in children[J]. Hepatology, 2008, 48 (4Suppl) : 855A.
10Wang K, Lawal A A, Majchrowicz M, et al. Pharmacokinetics of ribavirin in patients with renal impairment or end-stage renal disease and chronic hepatitis C during treatment with peginterferon alfa-2a (40KD) (PEGASYS) and RBV ( COPEGUS) [J]. Hepatology, 2008, 48(4Suppl): 1142A.
